Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record.

Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas

Rwigema, Jean-Claude M., Parikh, Simul D., Heron, Dwight E., Howell, Michael, Zeh, Herbert, Moser, A. James, Bahary, Nathan, Quinn, Annette, Burton, Steven A. · 2011 · American Journal of Clinical Oncology

Abstract

OBJECTIVES: The aim of the study was to assess the feasibility and safety of stereotactic body radiotherapy (SBRT) in patients with advanced pancreatic adenocarcinoma. METHODS: We reviewed outcomes of 71 patients treated with SBRT for pancreatic cancer between July 2004 and January 2009. Forty patients (56%) had locally unresectable disease, 11 patients (16%) had local recurrence following surgical resection, 8 patients (11%) had metastatic disease, and 12 patients (17%) received adjuvant SBRT for positive margins. The median dose was 24 Gy (18-25 Gy), given in a single-fraction SBRT (n = 67) or fractionated SBRT (n = 4). Kaplan-Meyer survival analyses were used to estimate freedom from local progression (FFLP) and overall survival (OS) rates. RESULTS: The median follow-up among surviving patients was 12.7 months (4-26 months). The median tumor volume was 17 mL (5.1-249 mL). The overall FFLP rates at 6 months/1 year were 71.7%/48.5%, respectively. Among those with macroscopic disease, FFLP was achieved in 77.3% of patients with tumor size <15 mL (n = 22), and 59.5% for ≥15 mL (n = 37) (P = 0.02). FFLP was achieved in 73% following 24 to 25 Gy, and 45% with 18 to 22 Gy (P = 0.004). The median OS was 10.3 months, with 6 month/1 year OS rates of 65.3%/41%, respectively. Grade 1-2 acute and late GI toxicity were seen in 39.5% of patients. Three patients experienced acute grade 3 toxicities. CONCLUSIONS: SBRT is feasible, with minimal grade ≥3 toxicity. The overall FFLP rate for all patients was 64.8%, comparable to rates with external beam radiotherapy. This shorter treatment course can be delivered without delay in adjuvant systemic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/coc.0b013e3181d270b4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Rwigema, J.-C. M., Parikh, S. D., Heron, D. E., Howell, M., Zeh, H., Moser, A. J., Bahary, N., Quinn, A., & Burton, S. A.
Venue
American Journal of Clinical Oncology
Published
2011-02
Volume
34
Issue
1
Pages
63-69
ISSN
0277-3732 (ISSN-L)
OpenAlex
W2086454079
Cited by
165
References
0
FWCI
4.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas. https://app.cochat.ai/papers/10.1097/coc.0b013e3181d270b4
The paper
Rwigema, J.-C. M., Parikh, S. D., Heron, D. E., Howell, M., Zeh, H., Moser, A. J., Bahary, N., Quinn, A., & Burton, S. A. (2011). Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0b013e3181d270b4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.